Last reviewed · How we verify
Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates
Approved treatments
- Aldactone · Pfizer Inc.
Aldosterone antagonist causing increased sodium and water excretion while retaining potassium.
Clinical guidelines
- FDA label — maintenance
Spironolactone is indicated for long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery. - FDA label — maintenance
Spironolactone is indicated for long-term maintenance for patients with bilateral micro or macronodular adrenal hyperplasia.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates patent landscape — cliff calendar, originator estates, attackable patents
- Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates treatment landscape brief
- Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates treatment updates RSS
Frequently asked questions about Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates
What drugs treat Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates?
Tracked treatments include Aldactone.
What is the treatment for Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates?
Standard treatment for Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates includes Aldactone. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates?
FDA label publishes guidelines for Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates. 2 guideline references tracked.
Related
- Treatment landscape: Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates patent cliff · Long-term maintenance therapy for discrete aldosterone-producing adrenal adenomas in non-surgical candidates CI report
- Treatment: Aldactone · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing